News | May 12, 2023
Gilead acquires XinThera to strengthen pipeline in oncology
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Specialty Chemicals grew 38% YoY for FY23
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
